BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...
TEL AVIV (MarketWatch) -- Novartis, the Basel drugmaker, said that the first clinical study of osteoporosis patients who have fractured a hip showed that its Reclast once-yearly injection "reduced the ...
You should not take Reclast if you're on Zometa® (zoledronic acid) Injection because it contains the same active ingredient. Additionally, you should not take Reclast if you are pregnant, plan to ...
Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...
The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...
Novartis Pharmaceuticals Corp. in East Hanover, an affiliate of Novartis AG, says it has received approval from the Food and Drug Administration for zoledronic acid (Reclast) injection as a ...
Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results